As per the outcomes of a randomized clinical trial, pregabalin displayed remarkable benefits in terms of response rate when evaluated by self-reporting of adequate relief, the dyspeptic symptom score (Global Overall Symptom scale), and quality of life (the short-form Nepean Dyspepsia Index scores) in patients with functional dyspepsia.

Researchers undertook this prospective, placebo-controlled, single-centre, double-blind study for determining pregabalin's efficacy and safety profile to treat functional dyspepsia. Participants diagnosed with functional dyspepsia  (age 18-70 years) and who did not respond well to proton pump inhibitors (n=72) were randomized to either pregabalin (75 mg daily) group (n=34) or placebo group (n=38) for eight weeks. A satisfactory relief response rate was the major endpoint, while improvement in pain scores, safety profile, and quality of life were the secondary endpoints.

Table 1 shows self-reported adequate relief rates and decrease in global symptoms in the study groups at weeks 4 and 8.

An improvement in overall quality of life was noted with pregabalin therapy. Dizziness was the most commonly reported adverse event with pregabalin therapy, occurring in about 51.6% of participants. However, it appeared to be well-tolerated following 1st week of therapy. Thus, pregabalin is beneficial to alleviate functional dyspepsia.